Based on these properties, recombinant GDF15 and GDF15 analogs have been explored as potential therapeutic agents for obesity, demonstrating robust weight loss effects in preclinical and early-phase clinical studies [38,39]. This evidence concerns the gene GDF15 and obesity due to melanocortin 4 receptor deficiency.